Tango Therapeutics, Inc. TNGX
25.73 USD +1.43 (+5.88%)
At closeNov 12, 2026, 7:00 AM EST
25.74 +0.01 +0.04%
Pre-market · Nov 12, 7:00 AM ET
23.87 Day range 26.41
7.49 52-week range 34.39
- YTD
- +190.41%
- 1 year
- +235.46%
- Market cap
- 4.36B
- EPS (ttm)
- -1.38
- Shares out
- 169.46M
- Forward P/E
- -14.28
- YTD return
- +190.41%
- 1-year return
- +235.46%
- Volume
- 3.87M
- Avg volume
- 3.39M
- Open
- 24.68
- Previous close
- 24.30
- Day's range
- 23.87 – 26.41
- 52-week range
- 7.49 – 34.39
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 47.00 (+82.7%)
- Earnings date
- Mar 4, 2027
5D +3.43 (+15.10%)
Key statistics
- Enterprise value
- 3.17B
- PEG ratio
- 0.00
- Price / book
- 4.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -80.18M
- Total cash
- 977.50M
- Total debt
- 31.18M
- Return on equity
- -36.48%
- Short % of float
- 28.83%
- 50-day average
- 23.35
- 200-day average
- 22.69
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.00 +82.7% upside
Now 25.73
- Target (low)
- 24.00
- Target (mean)
- 47.00
- Target (high)
- 68.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy1
- Buy11
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate -0.43433.
Financials — quick view
TNGX Revenue — quarterly 0
TNGX Net income — quarterly -68.39M
TNGX EPS — quarterly -0.39
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | -0.38 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.35297 | -0.39 | -0.04 | -10.49% |
| Aug 10, 2026 | Jun 30, 2026 | -0.31722 | -0.37 | -0.05 | -16.64% |
| May 13, 2026 | Mar 31, 2026 | -0.3137 | -0.32 | -0.01 | -2.01% |
| Mar 5, 2026 | Dec 31, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
| Nov 4, 2025 | Sep 30, 2025 | 0.01 | 0.13 | +0.12 | +1,200.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 10, 2026 | Wedbush | main | Outperform | Outperform |
| Nov 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 29, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tangotx.com
News
Tango Therapeutics (NASDAQ:TNGX) Stock Price Breaks Above 50-Day Moving Average After Earnings Miss 
JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47 
Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40 
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67 
Tango Therapeutics Q3 EPS $(0.39) Misses $(0.35) Estimate 
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights - HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target
Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings 
10 Health Care Stocks Whale Activity In Today’s Session 
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Your note
Sign in to keep a note on TNGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRY DOUGLAS | General Counsel | Sale | Feb 4, 2025 | 66,014 |
| BECKMAN DANIELLA | Chief Financial Officer | Sale | Feb 2, 2026 | 184,297 |
| CRYSTAL ADAM S | Officer | Sale | Nov 1, 2026 | 115,743 |
| GALL MATTHEW | Chief Financial Officer | Stock Award(Grant) | Apr 30, 2026 | 40,000 |
| KETCHUM JOHN B | Director | Stock Award(Grant) | Jun 4, 2026 | 24,937 |
| NEWCOMB JESSICA | Officer | Sale | Nov 1, 2026 | 52,090 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 8.20% | 13,900,620 | 357.66M | Jun 29, 2026 |
| FMR, LLC | 7.76% | 13,146,123 | 338.25M | Sep 29, 2026 |
| Blackrock Inc. | 7.34% | 12,438,444 | 320.04M | Jun 29, 2026 |
| Farallon Capital Management LLC | 7.24% | 12,277,000 | 315.89M | Jun 29, 2026 |
| Boxer Capital Management, LLC | 6.42% | 10,876,219 | 279.85M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 5.89% | 9,980,620 | 256.80M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.59% | 4,395,732 | 113.10M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.40% | 4,065,305 | 104.60M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.15% | 3,649,644 | 93.91M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.66% | 2,818,158 | 72.51M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.66% | 2,816,262 | 72.46M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.91% | 1,546,027 | 39.78M | Jun 29, 2026 |